Abe Bassan is a Principal at Samsara and joined the firm in 2017 when the fund was launched. He was previously Director of Program Biology at Revolution Medicines, where he co-led the initial stages of the company’s 4EBP1/mTORC1 cancer program. Prior to that, Abe was at bluebird bio, where he was the project manager for the company’s β-Thalassemia, Sickle Cell Anemia, and ALD gene therapy programs. Before bluebird, Abe was an Associate at Third Rock Ventures, where he was involved in the firm’s investment in bluebird bio and concept creation for Blueprint Medicines, a precision medicine oncology company. Abe was also the founder of Aurora Medical, a molecular diagnostics testing services company.
Abe received an AB in Molecular Biology from Princeton University, and an MS in Developmental Biology from Stanford University.